Glycine

BLOOD AND BLOOD FORMING ORGANS

Key facts

Glycine is a drug catalogued in DrugCentral. It was first approved by the FDA in 1976. DrugCentral lists 4 molecular targets, including OR51E2, Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a and Grin1. Recorded indications include Allergic rhinitis, Common cold, Cough and Nasal congestion.

• Molecular targets: OR51E2, Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a, Grin1 and SLC6A9 (4 listed in DrugCentral).
• Indications: Allergic rhinitis, Common cold, Cough, Nasal congestion and Nasal discharge and others.
• ATC code: B05CX03 (Other irrigating solutions).
• Molecular formula: C2H5NO2; molecular weight 75.07 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Allergic rhinitis
• Common cold
• Cough
• Nasal congestion
• Nasal discharge
• Rhinitis

Contraindications (18)

• Arteriosclerosis obliterans
• Classical phenylketonuria
• Constipation
• Dehydration
• End stage renal disease
• Heart disease
• Humoral hypercalcemia of malignancy
• Hypercalcemia
• Hypercalciuria
• Hyperparathyroidism
• Hyperphosphatemia
• Hypervitaminosis D
• Kidney disease
• Kidney stone
• Osteolysis
• Poisoning by digitalis glycoside
• Sarcoidosis
• Ventricular fibrillation

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Olfactory receptor 51E2	OR51E2	unknown	EC50 7.24
Glutamate NMDA receptor	Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a	unknown	Ki 6.77
Glutamate receptor ionotropic, NMDA 1	Grin1	unknown	IC50 6.60
Sodium- and chloride-dependent glycine transporter 1	SLC6A9	unknown	IC50 4.50

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-05-25	FDA	—	HOSPIRA

ATC classification

ATC code	Therapeutic hierarchy
B05CX03	BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › IRRIGATING SOLUTIONS › Other irrigating solutions

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Stevens-Johnson syndrome	81.3
Status epilepticus	73.0
Sopor	63.2
Skin laceration	61.5
Foetal growth restriction	56.0
Vasoplegia syndrome	44.6
Depressed level of consciousness	44.4
Compartment syndrome	44.3
Device related sepsis	41.0
Infantile apnoea	40.1
Coma scale abnormal	39.2
Pulse absent	37.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Glycine is on its molecule page.

• Molecular formula: C₂H₅NO₂
• Molecular weight: 75.07 g/mol
• CAS number: 56-40-6
• InChIKey: DHMQDGOQFOQNFH-UHFFFAOYSA-N
• PubChem CID: 750

NCC(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Glycine used for?

DrugCentral lists the following indications for Glycine: Allergic rhinitis, Common cold, Cough, Nasal congestion, Nasal discharge and Rhinitis.

How does Glycine work?

Its molecular targets in DrugCentral include OR51E2, Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a, Grin1 and SLC6A9.

When was Glycine first approved?

Glycine was first approved by the FDA in 1976.

What is the chemical formula of Glycine?

Glycine has the molecular formula C2H5NO2 and a molecular weight of 75.07 g/mol.

Sources

• DrugCentral drug card 1319 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL773 — compound record and bioactivity
• PubChem CID 750 — chemical identifiers
• DrugBank DB00145 — drug record
• FDA UNII TE7660XO1C — substance identity
• DailyMed: FDA labels for Glycine — current prescribing information (label search)
• UniProt Q9H255 (OR51E2) — target protein
• UniProt P48067 (SLC6A9) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.